Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.
Spring L, Goel S, Juric D, Isakoff S, Haddad S, Habin K, Krop I, Moy B, Tolaney S, Bardia A. Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial. Journal Of Clinical Oncology 2017, 35: tps1106-tps1106. DOI: 10.1200/jco.2017.35.15_suppl.tps1106.Peer-Reviewed Original ResearchHER2-positive metastatic breast cancerMetastatic HER2-positive breast cancerHER2-positive breast cancerObjective response rateProgression-free survivalMetastatic breast cancerT-DM1Breast cancerTrastuzumab emtansinePhase 1b clinical trialDose-expansion cohortsMTD/RP2DPhase 2 doseDose-escalation designPre-clinical modelsInhibition of CDK4/6Cyclin-dependent kinase 4Multiple effective therapiesHER receptor familyEligible patientsRECIST 1.1Most patientsPatient ageDependent kinase 4Escalation design